
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
Abstract
In a double-blind, randomized trial, a high dose of psilocybin produced large and sustained decreases in clinician-rated and self-rated measures of depressed mood and anxiety in patients with life-threatening cancer diagnoses. At 6-month follow-up, approximately 80% showed clinically significant decreases in depression and anxiety.
Keywords
psilocybincancerdepressionanxietyend-of-liferandomized trial
Clinical Research
